Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19: 2142-2132. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21: 891-896. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92: 1165-1171. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17: 3786-3792. Schiffer CA. Acute myeloid leukemia in adults: where do we go from here? Cancer Chemother Pharmacol. 2001;48(suppl): S45-S52. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Res Mod. 2002;20: 37-58. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem. 1992;35: 397-401. Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10: 23-29. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′ deoxyadenosine. Proc Natl Acad Sci U S A. 1992;89: 2970-2974. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res. 1995;55: 2847-2852. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-b-D-arabinofuranosyl) adenine. Cancer Res. 1996;56: 3030-3037. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21: 1167-1173. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102: 2379-2386. Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol. 1986;4: 1079-1088. Estey E, Plunkett W, Dixon DO, et al. Variables predicting response to high dose cytosine arabinoside therapy with refractory acute leukemia. Leukemia. 1987;1: 580-583. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-β-D-arabinosylcytosine-5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinosylcytosine therapy. Cancer Res. 1987;47: 3005-3011. Gandhi V, Plunkett W. Modulation of arabinosyl-nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48: 329-334. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11: 116-124. Gandhi V, Estey E, Keating MJ, et al. Chlorode-oxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87: 156-164. Parker WB, Shaddix SC, Rose L, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-β-D-ribofuranosy) adenine in CEM cells. Mol Pharmacol. 1999;55: 515-520. Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34: 485-491. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991;51: 2386-2394. Plunkett W, Hug V, Keating M, et al. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 1980;40: 588-591. Gandhi V, Chen W, Ayres M, et al. Plasma and cellular pharmacology of 8-cholor-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002;50: 85-94. Rodriguez CO Jr, Plunkett W, Paff MT, et al. A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatography B. 2000; 745: 421-430. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. In press. Estey EH, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9: 343-350. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10(suppl 1): 109-114. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of `poor risk' acute myeloid leukemias. Leukemia. 1994;8: 1842-1846. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73: 265-271. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25: 579-583. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58: 105-109. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 2001; 112: 127-137. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;101: 425-432. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003;9: 6335-6342. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103: 784-789. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus ara-C induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus ara-C without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12: 671-678. Kornblau SM, Gandhi V, Andreeff M, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10: 1563-1569. Crews KR, Gandhi V, Srivastava DK, et al. Evaluation of continuous infusion versus bolus infusion of cytarabine in combination with cladribine in pediatric acute myeloid leukemia: an interim analysis. J Clin Oncol. 2002;20: 4217-4224. Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res. 1998;4: 45-52. Kantarjian H, Estey EH, Plunkett W, et al. Phase I-II and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986;81: 387-394. Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose ara-C. Neurology. 1985;35: 1475-1479. Kornblau S, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993;7: 378-383.